June 29 (Reuters) - Cara Therapeutics Inc:
* Cara Therapeutics announces top-line results from phase 2B trial of oral CR845 in chronic pain patients with osteoarthritis of the hip or knee
* Cara Therapeutics Inc - all tablet strengths well tolerated over eight-week treatment period
* Cara Therapeutics Inc - 35 percent reduction in mean joint pain score for all patients at eight weeks with 5.0 mg dose
* Cara Therapeutics Inc - statistically significant 39 percent reduction in mean joint pain score in hip patients at eight weeks with 5.0 mg dose Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.